TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03873402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ipilimumab placebo
Description: Specified dose on specified days
Study: NCT02498756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: CIK cells are transferred every 3 months for 1 year.
Study: NCT01162876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxaglipitin
Description: oral administration of 5 mg tablet before breakfast for 14 consecutive days
Study: NCT02498756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab are delivered every 3 weeks for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab are delivered every 3 weeks for one year
Study: NCT03357146

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: OCTA scans per built-in device protocol

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: OCTA scans per built-in device protocol
Study: NCT00037635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study: NCT00209521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fospropofol
Description: Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
Study: NCT03653403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: Component A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Gel
Description: gel
Study: NCT02626845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
Study: NCT01202721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol or matching placebo 25 mg up-titrated to 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan or matching placebo 40 mg up-titrated to 80mg.
Study: NCT00247182

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Step 1: Minimal Intervention
Description: All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Step 2: Brief Motivational Intervention
Description: Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step 2: Brief Motivational Intervention
Description: Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Assessment
Description: Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
Study: NCT03265743

Intervention type: OTHER
Intervention: Self-report Written Questionnaire
Description: Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
Study: NCT03798249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Tereos

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nestlé Health Science
Study: NCT01547910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil given in supplementary dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil
Description: Fish oil given in supplementary dose
Study: NCT02725827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EmbryoGlue (Vitrolife)
Description: A hyaluronan-enriched embryo transfer medium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control medium
Description: The usual embryo transfer medium used in the study centres.
Study: NCT02474524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health intervention
Description: Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social intervention
Description: Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
Study: NCT03802708

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metabolomic analysis urine sample
Description: a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
Study: NCT04178239

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI, questionnaires, pneumologic diagnostics
Description: fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI, questionnaires, pneumologic diagnostics
Description: fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
Study: NCT02178111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Never perform episiotomy
Description: In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
Study: NCT03923699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Control Tower monitoring
Description: Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
Study: NCT02178111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: episiotomy
Study: NCT03045354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Description: Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional breakfast
Description: Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast skipping
Description: No breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: French fries
Description: Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beans
Description: Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
Study: NCT00629941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study: NCT04004468

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Standard barbell resistance training programs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Standard barbell resistance training programs
Study: NCT01135511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Eye drops
Description: Ophthalmic topical solution, low dose, dosed once/day, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Eye drops
Description: Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Eye drops
Description: Ophthalmic topical solution, high dose, dosed once/day, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550 Eye drops-vehicle
Description: Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Ophthalmic topical solution, dosed 6 times/day, 8 weeks
Study: NCT02748265

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Epoprostenol and phenylephrine
Description: After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Epoprostenol and phenylephrine
Description: After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Volatile maintenance anesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Intravenous maintenance anesthesia
Study: NCT04679571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin \>3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin \>3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year.
Study: NCT04813419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1927nm thulium laser
Description: The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5\*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2940nm Er:YAG laser
Description: The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
Study: NCT01814033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: LRU Pillow
Description: Foam wedge with a trough for positioning of the lower leg in an elevated position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Standard bed pillows placed under the lower leg to facilitate elevation
Study: NCT03401190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620 Injectable Emulsion (Low Dose)
Description: CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620 Injectable Emulsion (High Dose)
Description: CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
Study: NCT04363346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
Study: NCT01434004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations.
Study: NCT02748447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated FiO2 adjustment
Description: AVEA ventilator according to SpO2 target range delivers an automated FiO2
Study: NCT06278493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsules
Description: AL2846 is a multi -target receptor tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: It is a chemotherapeutic drug.
Study: NCT02684461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.
Study: NCT04259216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT Intervention
Description: Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Enhanced Online Resources (EOR)
Description: EOR group participants will receive standardized information on cyberbullying.
Study: NCT01744015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Making tool
Description: The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
Study: NCT02249078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: E6011 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: E6011 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: E6011 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: E6011 solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2-mL vial solution for injection
Study: NCT01664624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to roflumilast
Description: Placebo-matching roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to alogliptin
Description: Placebo-matching alogliptin tablets
Study: NCT02755961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on phosphate binder use
Study: NCT01846026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: compare how vitamin D influences the course of ulcerative colitis versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01126073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin/laropiprant
Description: After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
Study: NCT02350452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser coagulation
Description: Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation
Description: Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
Study: NCT00192491

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: Nasal Sprayer of one dosage of FluMist and other experimental

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: Nasal sprayer of FluMist